

Guenka Petrova

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1493191/publications.pdf>

Version: 2024-02-01

126
papers

1,695
citations

361413

20
h-index

361022

35
g-index

126
all docs

126
docs citations

126
times ranked

1930
citing authors

#	ARTICLE	IF	CITATIONS
1	Policies for biosimilar uptake in Europe: An overview. PLoS ONE, 2017, 12, e0190147.	2.5	153
2	EQ-5D in Central and Eastern Europe: 2000â€“2015. Quality of Life Research, 2016, 25, 2693-2710.	3.1	103
3	Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets. Frontiers in Public Health, 2018, 6, 328.	2.7	102
4	Use of complementary and alternative medicine by children in Europe: Published data and expert perspectives. Complementary Therapies in Medicine, 2013, 21, S34-S47.	2.7	100
5	The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications. Pharmacoeconomics, 2017, 35, 1271-1285.	3.3	94
6	Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria. European Journal of Health Economics, 2014, 15, 13-25.	2.8	70
7	Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries. Frontiers in Pharmacology, 2017, 8, 288.	3.5	50
8	Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 527-540.	1.4	48
9	Use of biologics for psoriasis in Central and Eastern European countries. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2222-2230.	2.4	41
10	Pharmacotherapeutic interventions for bipolar disorder type II: addressing multiple symptoms and approaches with a particular emphasis on strategies in lower and middle-income countries. Expert Opinion on Pharmacotherapy, 2019, 20, 2237-2255.	1.8	38
11	Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation. Frontiers in Pharmacology, 2017, 8, 497.	3.5	34
12	The European challenges of funding orphan medicinal products. Orphanet Journal of Rare Diseases, 2018, 13, 184.	2.7	34
13	Proposal for a regulation on health technology assessment in Europe â€“ opinions of policy makers, payers and academics from the field of HTA. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 251-261.	1.4	31
14	Pricing of oral generic cancer medicines in 25 European countries; findings and implications. GaBI Journal, 2019, 8, 49-70.	0.3	31
15	Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis. Frontiers in Pharmacology, 2018, 9, 1070.	3.5	30
16	Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review. Frontiers in Pharmacology, 2017, 8, 892.	3.5	27
17	Low fresh gas flow balanced anesthesia versus target controlled intravenous infusion anesthesia in laparoscopic cholecystectomy: A cost-minimization analysis. Clinical Therapeutics, 2008, 30, 1714-1725.	2.5	24
18	A Cross-Sectional Survey on Medication Management Practices for Noncommunicable Diseases in Europe During the Second Wave of the COVID-19 Pandemic. Frontiers in Pharmacology, 2021, 12, 685696.	3.5	24

#	ARTICLE	IF	CITATIONS
19	Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts. <i>BioMed Research International</i> , 2018, 2018, 1-9.	1.9	23
20	Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines. <i>Frontiers in Pharmacology</i> , 2018, 9, 794.	3.5	22
21	Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries. <i>Frontiers in Pharmacology</i> , 2019, 10, 487.	3.5	22
22	The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future. <i>Frontiers in Public Health</i> , 2021, 9, 671961.	2.7	22
23	Complex Regional Pain Syndrome Acceptance and the Alternative Denominations in the Medical Literature. <i>Medical Principles and Practice</i> , 2013, 22, 295-300.	2.4	21
24	Cost of severe hypoglycaemia in nine European countries. <i>Journal of Medical Economics</i> , 2016, 19, 973-982.	2.1	21
25	Life expectancy and survival analysis of patients with diabetes compared to the non diabetic population in Bulgaria. <i>PLoS ONE</i> , 2020, 15, e0232815.	2.5	21
26	Rationalizing the introduction and use of pharmaceutical products: The role of managed entry agreements in Central and Eastern European countries. <i>Health Policy</i> , 2018, 122, 230-236.	3.0	20
27	EQ-5D studies in cardiovascular diseases in eight Central and Eastern European countries: a systematic review of the literature. <i>Kardiologia Polska</i> , 2018, 76, 860-870.	0.6	19
28	Evaluation of consumer satisfaction using the tetra-class model. <i>Research in Social and Administrative Pharmacy</i> , 2008, 4, 258-271.	3.0	18
29	Assessment of the expectancy, seriousness and severity of adverse drug reactions reported for chronic obstructive pulmonary disease therapy. <i>SAGE Open Medicine</i> , 2017, 5, 205031211769040.	1.8	18
30	European Network to Advance Best Practices and Technology on Medication Adherence: Mission Statement. <i>Frontiers in Pharmacology</i> , 2021, 12, 748702.	3.5	17
31	Pilot project for education of patients with type 2 diabetes by pharmacists. <i>Acta Diabetologica</i> , 2006, 43, 37-42.	2.5	16
32	Comparison of health-related quality-of-life measurement instruments in diabetic patients. <i>Biotechnology and Biotechnological Equipment</i> , 2014, 28, 769-774.	1.3	16
33	Influence of COVID-19 on Health-Related Quality of Life and the Perception of Being Vaccinated to Prevent COVID-19: An Approach for Community Pharmacists from Romania and Bulgaria. <i>Journal of Clinical Medicine</i> , 2021, 10, 864.	2.4	14
34	Health technology assessment in the Balkans: opportunities for a balanced drug assessment system. <i>Biotechnology and Biotechnological Equipment</i> , 2014, 28, 1181-1189.	1.3	13
35	Clinical characteristics, treatment patterns, and socio-economic burden of COPD in Bulgaria. <i>Journal of Medical Economics</i> , 2017, 20, 503-509.	2.1	13
36	Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries. <i>Frontiers in Pharmacology</i> , 2018, 9, 795.	3.5	13

#	ARTICLE	IF	CITATIONS
37	New Epidemiological, Clinical and Economic Data for Patients With Acromegaly in Bulgaria. <i>Frontiers in Public Health</i> , 2020, 8, 147.	2.7	12
38	A Systematic Review of Collective Evidences Investigating the Effect of Diabetes Monitoring Systems and Their Application in Health Care. <i>Frontiers in Endocrinology</i> , 2021, 12, 636959.	3.5	12
39	Benefits of investment into modern medicines in Central and Eastern European countries. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 71-79.	1.4	11
40	"Without data, you're just another person with an opinion". <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 147-154.	1.4	11
41	A Cross-Country Comparison of Reimbursed Orphan Medicines in Bulgaria, Greece and Romania. <i>Biotechnology and Biotechnological Equipment</i> , 2013, 27, 4186-4192.	1.3	9
42	Cost of hospitalizations due to microvascular and macrovascular complications in type 1 and type 2 diabetic patients in Bulgaria. <i>Biotechnology and Biotechnological Equipment</i> , 2015, 29, 805-813.	1.3	9
43	EQ-5D studies in musculoskeletal and connective tissue diseases in eight Central and Eastern European countries: a systematic literature review and meta-analysis. <i>Rheumatology International</i> , 2017, 37, 1957-1977.	3.0	9
44	Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 277.	2.7	9
45	Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges. <i>Frontiers in Public Health</i> , 2020, 8, 612410.	2.7	9
46	Economic evaluation of continuous subcutaneous insulin infusion for children with diabetes - a pilot study: CSII application for children - economic evaluation. <i>BMC Pediatrics</i> , 2013, 13, 155.	1.7	8
47	Economic evaluation of different screening alternatives for patients with clinically suspected acute deep vein thrombosis. <i>Biochemia Medica</i> , 2013, 23, 96-106.	2.7	8
48	ISO 9001 certification for hospitals in Bulgaria: does it help service?. <i>Biotechnology and Biotechnological Equipment</i> , 2014, 28, 372-378.	1.3	8
49	EQ-5D studies in nervous system diseases in eight Central and East European countries: a systematic literature review. <i>European Journal of Health Economics</i> , 2019, 20, 109-117.	2.8	8
50	Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria. <i>Pharmaceuticals</i> , 2021, 14, 64.	3.8	8
51	Pharmacist's Perspectives on Administering a COVID-19 Vaccine in Community Pharmacies in Four Balkan Countries. <i>Frontiers in Public Health</i> , 2021, 9, 766146.	2.7	8
52	Impact of generic competition on market share and prices of cardiovascular medicines on the Bulgarian pharmaceutical market. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2011, 19, 91-100.	1.6	7
53	Real World Experience of Disease Activity in Patients With Rheumatoid Arthritis and Response to Treatment With Various Biologic DMARDs. <i>Frontiers in Pharmacology</i> , 2018, 9, 1303.	3.5	7
54	Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications. <i>BioMed Research International</i> , 2021, 2021, 1-16.	1.9	7

#	ARTICLE	IF	CITATIONS
55	Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	7
56	Utilization and Price Trends in Some Reimbursed Cardiovascular Medicines. <i>Biotechnology and Biotechnological Equipment</i> , 2011, 25, 2424-2431.	1.3	6
57	Comparative Analysis of the Cost of Insulin Treated Patients in Bulgaria. <i>Biotechnology and Biotechnological Equipment</i> , 2013, 27, 3748-3752.	1.3	6
58	Chronic obstructive pulmonary disease exacerbations and progression in relation to ambient air pollutants exposure. <i>Journal of Thoracic Disease</i> , 2019, 11, 2490-2497.	1.4	6
59	Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 733-742.	1.4	6
60	Comparative analysis of the access to health-care services and breast cancer therapy in 10 Eastern European countries. <i>SAGE Open Medicine</i> , 2020, 8, 205031212092202.	1.8	6
61	Reimbursed Orphan Medicines in Bulgaria and the Share of Biotechnology-Derived Products. <i>Biotechnology and Biotechnological Equipment</i> , 2011, 25, 2418-2423.	1.3	5
62	Enantiomers Novelty Protection and its Influence on Generic Market: An Example with Escitalopram Patent Protection. <i>Biotechnology and Biotechnological Equipment</i> , 2013, 27, 4044-4047.	1.3	5
63	Orphan medicinal productsâ€™ access to the Bulgarian pharmaceutical market â€“ challenges and obstacles. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 95-104.	0.8	5
64	Costs and outcomes for individuals with psychosis prior to hospital admission and following discharge in Bulgaria. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2019, 54, 1353-1362.	3.1	5
65	Availability and reimbursement of biological products for severe asthma in Bulgaria. <i>SAGE Open Medicine</i> , 2020, 8, 205031212095106.	1.8	5
66	Do Advanced Therapies Have a Future in the Low- and Middle-Income Countries - The Case of Bulgaria, Romania, and Poland. <i>Frontiers in Public Health</i> , 2021, 9, 729847.	2.7	5
67	The applicability of the tetraclass model to the management of the patient satisfaction in the pharmacies. <i>Pharmacy Practice</i> , 2009, 7, 19-28.	1.5	5
68	Pharmacy network and access to medicines in selected eastern European countries: comparative analysis. <i>Croatian Medical Journal</i> , 2012, 53, 53-59.	0.7	4
69	The Cost-Effectiveness of Hypertension Pharmacotherapy in Serbia: A Markov Model. <i>Biotechnology and Biotechnological Equipment</i> , 2012, 26, 3066-3072.	1.3	4
70	Cost-Effectiveness of Biphasic Insulin Aspart 30 VS. Human Premix Insulin in Type 2 Diabetes from the Payer's Perspective in Bulgaria. <i>Biotechnology and Biotechnological Equipment</i> , 2012, 26, 2937-2944.	1.3	4
71	Generic policy in Bulgaria: a policy of failure or success?. <i>Biotechnology and Biotechnological Equipment</i> , 2016, 30, 1031-1037.	1.3	4
72	Cost-effectiveness of short COH protocols with GnRH antagonists using different types of gonadotropins for <i>in vitro</i> fertilization. <i>Biotechnology and Biotechnological Equipment</i> , 2016, 30, 614-621.	1.3	4

#	ARTICLE	IF	CITATIONS
73	An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries. <i>Frontiers in Public Health</i> , 2018, 6, 61.	2.7	4
74	Cost-effectiveness analysis in diagnosis of coronary artery disease: Choice of laboratory markers. <i>Clinical Biochemistry</i> , 2007, 40, 1180-1187.	1.9	3
75	Economic Analysis 20 Years after the Introduction of Universal HBV Immunisation in Bulgaria. <i>Biotechnology and Biotechnological Equipment</i> , 2012, 26, 2811-2816.	1.3	3
76	Budget Impact Analysis of Chronic Myeloid Leukemia Treatment in Bulgaria. <i>Biotechnology and Biotechnological Equipment</i> , 2013, 27, 3595-3598.	1.3	3
77	Economic Impact of the Highly Active Antiretroviral Pharmacotherapy on Cost and HIV/AIDS Control in Bulgaria. <i>Biotechnology and Biotechnological Equipment</i> , 2013, 27, 3599-3604.	1.3	3
78	Economic consequences of the vaccination against hepatitis A in the Bulgarian healthcare setting. <i>Biotechnology and Biotechnological Equipment</i> , 2014, 28, 366-371.	1.3	3
79	Chronic Hepatitis C-Related Cirrhosis Hospitalization Cost Analysis in Bulgaria. <i>Frontiers in Medicine</i> , 2017, 4, 125.	2.6	3
80	Is There a Symmetry in Disease Control and Quality of Life of Patients with Rheumatoid Arthritis Treated with Biological Therapy?. <i>Symmetry</i> , 2021, 13, 538.	2.2	3
81	Analysis of the Household and Health Care System Expenditures in Bulgaria. <i>Frontiers in Public Health</i> , 2021, 9, 675277.	2.7	3
82	Cost of outpatient hypertension pharmacotherapy: comparative study between Bulgaria and Serbia. <i>Pharmacy Practice</i> , 2009, 7, 108-12.	1.5	3
83	Assessment of the social and economic burden of glaucoma in Bulgaria. <i>Biomedical Research (Aligarh)</i> , 2017, 28(1), 107-114.	0.1	3
84	Pharmaceutical Biotechnology in Pharmacy Education: USA Pharmacy Schools. <i>Biotechnology and Biotechnological Equipment</i> , 2011, 25, 2533-2537.	1.3	2
85	Budget Impact Model of New Antiretroviral Biotechnology Medicines for Treatment of HIV/AIDS Patients in Bulgaria. <i>Biotechnology and Biotechnological Equipment</i> , 2011, 25, 2547-2554.	1.3	2
86	Patent Protection Policy in the Therapeutic Group of Statins. <i>Biotechnology and Biotechnological Equipment</i> , 2011, 25, 2683-2687.	1.3	2
87	The Health Related Quality of Life for Kidney Transplant Patients in Bulgaria – A Pilot Study. <i>Biotechnology and Biotechnological Equipment</i> , 2012, 26, 3062-3065.	1.3	2
88	Chirality as a Patent Protection Policy – An Example with Citalopram. <i>Biotechnology and Biotechnological Equipment</i> , 2012, 26, 3058-3061.	1.3	2
89	Pharmaceutical Biotechnology Education in the Pharmacy Curriculum at European Universities. <i>Biotechnology and Biotechnological Equipment</i> , 2012, 26, 3187-3191.	1.3	2
90	Quality Management in Pharmaceutical Procurement: Most Frequent Non-Conformities in Pharmaceutical Wholesalers in Bulgaria. <i>Biotechnology and Biotechnological Equipment</i> , 2013, 27, 4193-4196.	1.3	2

#	ARTICLE	IF	CITATIONS
91	Cost-effectiveness of different types of COH protocols for in vitro fertilization at national level. <i>Biotechnology and Biotechnological Equipment</i> , 2017, 31, 206-214.	1.3	2
92	Improved quality of diabetes control reduces complication costs in Bulgaria. <i>Biotechnology and Biotechnological Equipment</i> , 2019, 33, 814-820.	1.3	2
93	Pilot Study on the Cost of Some Oncohematology Diseases in Bulgaria. <i>Frontiers in Public Health</i> , 2019, 7, 70.	2.7	2
94	Economic and pharmaco-economic analysis of acromegaly treatment: a systematic review. <i>Biotechnology and Biotechnological Equipment</i> , 2019, 33, 1560-1571.	1.3	2
95	On affordability of statins therapy - comparative analysis between Ukraine and Bulgaria. <i>BMC Health Services Research</i> , 2019, 19, 902.	2.2	2
96	Analysis of patients' access to reimbursed biotechnological medicines for multiple sclerosis in Bulgaria and Greece. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 241-246.	1.4	2
97	Screening and diagnosis of chronic HCV infection in Bulgaria: A review of the current practice. <i>Biomedical Research (Aligarh, India)</i> , 2018, 29, .	0.1	2
98	Financial Analysis of the Access to Pharmacotherapy for Rare Diseases in Bulgaria. <i>Modern Economy</i> , 2014, 05, 461-467.	0.5	2
99	Modelling the Financial Framework of the Pharmacotherapy Cost of Rare Diseases with Orphan Medicines – Part II. <i>Modern Economy</i> , 2014, 05, 499-505.	0.5	2
100	ACCESS TO ORPHAN DRUGS: A CROSS COUNTRY COMPARISON OF LEGISLATIVE APPROACH AMONG SERBIA, CROATIA AND MACEDONIA. <i>Acta Medica Medianae</i> , 2018, 57, 43-51.	0.1	2
101	A HEALTH-RELATED QUALITY OF LIFE AND PHARMACOTHERAPY COSTS STUDY FOR PATIENTS WITH CYSTIC FIBROSIS, GAUCHER DISEASE AND CHRONIC MYELOID LEUKEMIA IN BULGARIA. <i>Biotechnology and Biotechnological Equipment</i> , 2013, 27, 3896-3900.	1.3	2
102	Impact of Discounting in Pharmacoeconomic Modeling. A Case Study. <i>Biotechnology and Biotechnological Equipment</i> , 2011, 25, 2555-2558.	1.3	1
103	Generics and fixed-dose combinations in cardiology: satisfaction analysis of pharmacists and cardiologists. <i>Biotechnology and Biotechnological Equipment</i> , 2016, 30, 204-211.	1.3	1
104	Medical, social, and economic consequences of type 2 diabetes therapy with medicinal products from the group of DPP-4i, SGLT-2i, and GLP-1 RA. <i>International Journal of Diabetes in Developing Countries</i> , 2018, 38, 520-521.	0.8	1
105	Cost-effectiveness analysis of current treatment of individuals with acute exacerbation of schizophrenia in Bulgaria. <i>Biotechnology and Biotechnological Equipment</i> , 2019, 33, 204-213.	1.3	1
106	Cardiovascular co-morbidity in patients with COPD in Bulgaria. <i>Biotechnology and Biotechnological Equipment</i> , 2020, 34, 918-924.	1.3	1
107	Comparison of Cardiovascular Medicines Prices in Four European Countries. <i>Frontiers in Public Health</i> , 2020, 8, 433.	2.7	1
108	Pharmacotherapeutic Patterns and Patients' Access to Pharmacotherapy for Some Rare Diseases in Bulgaria – A Pilot Comparative Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 695181.	3.5	1

#	ARTICLE	IF	CITATIONS
109	Cost-effectiveness analysis of different types of labor for singleton pregnancy: Real life data. Srpski Arhiv Za Celokupno Lekarstvo, 2014, 142, 688-694.	0.2	1
110	Statins utilization and price variations-comparison between Ukraine and Bulgaria. Biomedical Research (Aligarh, India), 2018, 29, .	0.1	1
111	Cost-effectiveness of in vitro fertilization and controlled ovarian hyperstimulation before and after the COVID-19 outbreak. Biotechnology and Biotechnological Equipment, 2021, 35, 1820-1826.	1.3	1
112	Double Celebration: Two Notable Bulgarian Academicians and Co-Founders of Diagnosis Pressâ„¢ Turned 70 this Year. Biotechnology and Biotechnological Equipment, 2013, 27, 4049-4050.	1.3	0
113	Humanistic and economic aspects of haemophilia treatment in Bulgaria. Comparison between two therapeutic approaches: prophylactic vs. on-demand treatment. Biotechnology and Biotechnological Equipment, 2014, 28, 576-582.	1.3	0
114	Cost-Minimization Analysis of Direct Cost of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Patients with Chronic Kidney Disease Not on Dialysis in Bulgaria. Value in Health Regional Issues, 2015, 7, 94-103.	1.2	0
115	Incretins and SGLT-2i Therapy of Type 2 Diabetes â€œ Real Life Study of Their Therapeutic and Economic Effects. Frontiers in Pharmacology, 2019, 10, 364.	3.5	0
116	Economic consequences of the implementation of national screening program for chronic HCV infection. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 20, 397-404.	1.4	0
117	Triple negative breast cancer in Bulgaria: epidemiological data and treatment patterns based on real world evidence and patient registries. Biotechnology and Biotechnological Equipment, 2021, 35, 551-559.	1.3	0
118	Biosimilar Insulins and Their Impact on Prices and Utilization of Insulins in Bulgaria. Healthcare (Switzerland), 2021, 9, 697.	2.0	0
119	Review of medicine utilization for Parkinsonâ€™s disease management: the Bulgarian perspective. Journal of Public Health Research, 2021, , .	1.2	0
120	How much do we pay for caesarean section: A pilot study in Serbia. Acta Chirurgica Iugoslavica, 2013, 60, 47-51.	0.0	0
121	Efficacy and Safety of Reimbursed Orphan Medicines in Bulgaria â€œ Systematic Review and Meta-analysis (Part I). Journal of Pharmaceutical Research International, 2017, 17, 1-14.	1.0	0
122	Inhaled corticosteroids in stable COPD â€œ international recommendations and reality in Bulgaria. , 2017, , .		0
123	BUDGET IMPACT ANALYSIS OF INHIBITOR HAEMOPHILIA A THERAPY WITH BYPASSING AGENTS. Journal of IMAB, 2019, 25, 2511-2515.	0.1	0
124	Utilization, Cost, and Affordability of Antihypertensive Therapy in Bulgaria. Iranian Journal of Pharmaceutical Research, 2021, 20, 403-416.	0.5	0
125	Volume and trends of adalimumab and pembrolizumab reimbursed market: the Bulgarian perspective. Biotechnology and Biotechnological Equipment, 2021, 35, 1778-1791.	1.3	0
126	Quality of life and disease activity of patients with rheumatoid arthritis on tofacitinib and biologic disease-modifying antirheumatic drug therapies. Rheumatology International, 0, , .	3.0	0